When B cells break bad: development of pathogenic B cells in Sjogren's syndrome
Details
Publication Year 2020-09-22,Volume 38 Suppl 126,Issue #4,Page 271-282
Journal Title
Clinical and Experimental Rheumatology
Publication Type
Journal Article
Abstract
Primary Sjogren's syndrome (pSS) is often considered a B cell-mediated disease, yet the precise role of B cells in the pathogenesis is not fully understood. This is exemplified by the failure of multiple clinical trials directed at B cell depletion or inhibition. To date, most prognostic markers for severe disease outcomes are autoantibodies, but the underlying mechanisms by which B cells drive diverse disease presentations in pSS likely extend beyond autoantibody production. Here we outline an expanded role of B cells in disease pathogenesis drawing on examples from animal models of SS, and from other autoimmune diseases that share similar clinical or immunological abnormalities. We focus on recent findings from the detailed analysis of pathogenic B cells in patients with pSS to propose strategies for patient stratification to improve clinical trial outcomes. We conclude that an integrated cellular, molecular and genetic analysis of patients with pSS will reveal the underlying pathogenic mechanisms and guide precision medicine.
Publisher
CER
Research Division(s)
Immunology
PubMed ID
33025890
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2020-10-17 02:40:35
Last Modified: 2020-11-03 10:14:02
An error has occurred. This application may no longer respond until reloaded. Reload 🗙